Pancreatic Cancer Treatment
~ Genetics of Breast & Ovarian Cancer

Treatment for HBOC- or BRCA1/2 mutation-related pancreatic cancer

List was last updated on Jan 17, 2021 @ 9:51 pm.


    • Clinical Significance of Germline Cancer Predisposing Variants in Unselected Patients with Pancreatic Adenocarcinoma.
    • Fountzilas E, Eliades A, Koliou GA, Achilleos A, Loizides C, Tsangaras K, Pectasides D, Sgouros J, Papakostas P, Rallis G, Psyrri A, Papadimitriou C, Oikonomopoulos G, Ferentinos K, Koumarianou A, Zarkavelis G, Dervenis C, Aravantinos G, Bafaloukos D, Kosmidis P, Papaxoinis G, Theochari M, Varthalitis I, Kentepozidis N, Rigakos G, Saridaki Z, Nikolaidi A, Christopoulou A, Fostira F, Samantas E, Kypri E, Ioannides M, Koumbaris G, Fountzilas G, Patsalis PC.
    • Cancers (Basel). 2021 Jan 8;13(2):E198. doi: 10.3390/cancers13020198.
    • A novel somatic BRCA2 point mutation in a metastatic pancreatic cancer patient: a case report.
    • Wang D, Guan R, Tao Q, Liu S, Yu M, Li X.
    • BMC Med Genomics. 2021 Jan 6;14(1):6. doi: 10.1186/s12920-020-00850-6.
    • Japanese Regulators Approve Lynparza for Ovarian, Prostate, Pancreatic Cancers.
    • [No author given]
    • Precision Oncology News. 2020 Dec 28.
    • Poly(ADP-ribose) polymerase inhibition in pancreatic cancer.
    • Singh HM, Bailey P, Hübschmann D, Berger AK, Neoptolemos J, Jäger D, Siveke J, Springfeld C.
    • Genes Chromosomes Cancer. 2020 Dec 20. doi: 10.1002/gcc.22932. Epub ahead of print.
    • Review
    • Lynparza Cost-Effectiveness Analysis IDs Pancreatic Cancer Subgroups That Derive Most Benefit.
    • Kanski A.
    • Precision Oncology News. 2020 Dec 17.
    • Research news

    Related:

    Original research:

    Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

    • Cost-Effectiveness Analysis of Maintenance Olaparib in Patients with Metastatic Pancreatic Cancer and a Germline BRCA1/2 Mutation Based on the POLO Trial.
    • Zhan M, Zheng H, Yang Y, He Z, Xu T, Li Q.
    • Cancer Manag Res. 2020 Dec 16;12:12919-12926. doi: 10.2147/CMAR.S283169.
    • Pancreatic mucinous cystadenocarcinoma in a patient harbouring BRCA1 germline mutation effectively treated with olaparib: A case report.
    • Di Marco M, Carloni R, De Lorenzo S, Mosconi C, Palloni A, Grassi E, Filippini DM, Ricci AD, Rizzo A, Di Federico A, Santini D, Turchetti D, Ricci C, Ingaldi C, Alberici L, Minni F, Golfieri R, Brandi G, Casadei R.
    • World J Gastrointest Oncol. 2020 Dec 15;12(12):1456-1463. doi: 10.4251/wjgo.v12.i12.1456.
    • Update on the Role of Poly (ADP-Ribose) Polymerase Inhibitors in the DNA Repair-Deficient Pancreatic Cancers: A Narrative Review.
    • Kasi A, Al-Jumayli M, Park R, Baranda J, Sun W.
    • J Pancreat Cancer. 2020 Dec 4;6(1):107-115. doi: 10.1089/pancan.2020.0010.
    • Combinatorial efficacy of olaparib with radiation and ATR inhibitor requires PARP1 protein in homologous recombination proficient pancreatic cancer.
    • Parsels LA, Engelke CG, Parsels J, Flanagan SA, Zhang Q, Tanska D, Wahl DR, Canman CE, Lawrence TS, Morgan MA.
    • Mol Cancer Ther. 2020 Dec 2:molcanther.0365.2020. doi: 10.1158/1535-7163.MCT-20-0365. Epub ahead of print.
    • Novel poly (ADP-ribose) polymerases inhibitor DHC-1 exhibits in vitro and in vivo anticancer activity on BRCA-deficient pancreatic cancer cells.
    • Wu X, Li Q, Zhang F, Wang L, Wang J, Fan J, Di G, Guo C.
    • Food Chem Toxicol. 2020 Nov 30:111892. doi: 10.1016/j.fct.2020.111892. Epub ahead of print.
    • Olaparib in BRCA+ Pancreatic Cancer: Cost-effectiveness Analyzed.
    • Nelson R.
    • Medscape. Medical News. 2020 Nov 19.

    Related:

    Original research:

    Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

    • BRCA in Gastrointestinal Cancers: Current Treatments and Future Perspectives.
    • Molinaro E, Andrikou K, Casadei-Gardini A, Rovesti G.
    • Cancers (Basel). 2020 Nov 12;12(11):E3346. doi: 10.3390/cancers12113346.
    • Cost-Effectiveness of Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
    • Wu B, Shi L.
    • J Natl Compr Canc Netw. 2020 Nov 2;18(11):1528-1536. doi: 10.6004/jnccn.2020.7587.

    Related:

    Press: Olaparib in BRCA+ Pancreatic Cancer: Cost-effectiveness Analyzed. (Medscape)

    Research news: Lynparza Cost-Effectiveness Analysis IDs Pancreatic Cancer Subgroups That Derive Most Benefit. (Precision Oncology News)

    • Molecular characteristics of BRCA1/2 and PALB2 mutations in pancreatic ductal adenocarcinoma.
    • Seeber A, Zimmer K, Kocher F, Puccini A, Xiu J, Nabhan C, Elliott A, Goldberg RM, Grothey A, Shields AF, Battaglin F, El-Deiry WS, Philip PA, Marshall JL, Hall M, Korn WM, Lenz HJ, Wolf D, Feistritzer C, Spizzo G.
    • ESMO Open. 2020 Nov;5(6):e000942. doi: 10.1136/esmoopen-2020-000942.
    • An evaluation of olaparib for the treatment of pancreatic cancer.
    • Vaishampayan UN.
    • Expert Opin Pharmacother. 2020 Oct 23. doi: 10.1080/14656566.2020.1837113. Epub ahead of print.
    • Review
    • Effect of germline mutations in homologous recombination repair genes on overall survival of patients with pancreatic adenocarcinoma.
    • Yadav S, Kasi PM, Bamlet WR, Ho TP, Polley EC, Hu C, Hart SN, Rabe KG, Boddicker NJ, Gnanaolivu RD, Lee KY, Lindstrom T, Petersen GM, Couch FJ, McWilliams RR.
    • Clin Cancer Res. 2020 Oct 7:clincanres.1788.2020. doi: 10.1158/1078-0432.CCR-20-1788. Epub ahead of print.
    • BRCA2 Reversion Mutation Identified by Liquid Biopsy After Durable Response to FOLFIRINOX in BRCA2-Associated Pancreatic Cancer.
    • Kondo T, Kanai M, Matsubara J, Quy PN, Fukuyama K, Yamamoto Y, Yamada T, Nishigaki M, Minamiguchi S, Takeda M, Nishio K, Matsumoto S, Muto M.
    • Pancreas. 2020 Oct 2. doi: 10.1097/MPA.0000000000001672. Epub ahead of print.
    • Genetic characterization of pancreatic cancer patients and prediction of carrier status of germline pathogenic variants in cancer-predisposing genes.
    • Mizukami K, Iwasaki Y, Kawakami E, Hirata M, Kamatani Y, Matsuda K, Endo M, Sugano K, Yoshida T, Murakami Y, Nakagawa H, Spurdle AB, Momozawa Y.
    • EBioMedicine. 2020 Sep 24;60:103033. doi: 10.1016/j.ebiom.2020.103033. Epub ahead of print.
    • PARP inhibition in treatment of pancreatic cancer.
    • Hammel P, Zhang C, Matile J, Colle E, Hadj-Naceur I, Gagaille MP, Bouattour M, Cros J, de Mestier L, Lamuraglia M.
    • Expert Rev Anticancer Ther. 2020 Sep 16:1-7. doi: 10.1080/14737140.2020.1820330. Epub ahead of print.
    • Review
    • Nouvelle AMM : olaparib — cancer du pancréas avec mutation germinale de BRCA [New drug approval: Olaparib - pancreatic cancer with BRCA germline mutation].
    • Hilmi M, Neuzillet C.
    • Bull Cancer. 2020 Sep 14:S0007-4551(20)30324-6. French. doi: 10.1016/j.bulcan.2020.06.009. Epub ahead of print.
    • Letter, News, [Article in French]
    • What is the role of PARP inhibitors in pancreatic cancer?
    • Halder R, T Shroff R.
    • Expert Rev Anticancer Ther. 2020 Sep 11:1-6. doi: 10.1080/14737140.2020.1816174. Epub ahead of print.
    • FoundationOne® CDx gene profiling in Japanese pancreatic ductal adenocarcinoma patients: a single-institution experience.
    • Kimura R, Ohtsuka T, Kubo M, Kajihara A, Fujii A, Watanabe Y, Mori Y, Ikenaga N, Nakata K, Shindo K, Ohuchida K, Nakamura M.
    • Surg Today. 2020 Sep 4. doi: 10.1007/s00595-020-02123-2. Epub ahead of print.
    • Novel mutations in BRCA2 intron 11 and overexpression of COX-2 and BIRC3 mediate cellular resistance to PARP inhibitors.
    • Chen HD, Guo N, Song SS, Chen CH, Miao ZH, He JX.
    • Am J Cancer Res. 2020 Sep 1;10(9):2813-2831.
    • DNA damage repair as a target in pancreatic cancer: state-of-the-art and future perspectives.
    • Perkhofer L, Gout J, Roger E, Kude de Almeida F, Baptista Simões C, Wiesmüller L, Seufferlein T, Kleger A.
    • Gut. 2020 Aug 27:gutjnl-2019-319984. doi: 10.1136/gutjnl-2019-319984. Epub ahead of print.
    • A new targeted treatment for patients with a germline BRCA mutation: olaparib in pancreatic cancer.
    • Verdaguer H, Acosta D, Macarulla T.
    • Future Oncol. 2020 Aug 17. doi: 10.2217/fon-2020-0334. Epub ahead of print.
    • Review
    • Precision medicine phase II study evaluating the efficacy of a double immunotherapy by durvalumab and tremelimumab combined with olaparib in patients with solid cancers and carriers of homologous recombination repair genes mutation in response or stable after olaparib treatment.
    • Fumet JD, Limagne E, Thibaudin M, Truntzer C, Bertaut A, Rederstorff E, Ghiringhelli F.
    • BMC Cancer. 2020 Aug 10;20(1):748. doi: 10.1186/s12885-020-07253-x.
    • BReast CAncer (BRCA) gene mutations as an emerging biomarker for the treatment of gastrointestinal malignancies.
    • Premnath N, O'Reilly EM.
    • Chin Clin Oncol. 2020 Aug 10:cco-2019-ddp-05. doi: 10.21037/cco-2019-ddp-05. Epub ahead of print.
    • Retrospective review of outcomes in patients with DNA-damage repair related pancreatic cancer.
    • Macklin-Mantia SK, Hines SL, Kasi PM.
    • Hered Cancer Clin Pract. 2020 Aug 10;18:17. doi: 10.1186/s13053-020-00148-9.
    • Metastatic Pancreatic Cancer: ASCO Guideline Update.
    • Sohal DPS, Kennedy EB, Cinar P, Conroy T, Copur MS, Crane CH, Garrido-Laguna I, Lau MW, Johnson T, Krishnamurthi S, Moravek C, O'Reilly EM, Philip PA, Pant S, Shah MA, Sahai V, Uronis HE, Zaidi N, Laheru D.
    • J Clin Oncol. 2020 Aug 5:JCO2001364. doi: 10.1200/JCO.20.01364. Epub ahead of print.
    • Excellent Response to Olaparib in a Patient with Metastatic Pancreatic Adenocarcinoma with Germline BRCA1 Mutation after Progression on FOLFIRINOX: Case Report and Literature Review.
    • Pimenta JR, Ueda SKN, Peixoto RD.
    • Case Rep Oncol. 2020 Jul 29;13(2):904-910. doi: 10.1159/000508533.
    • Advanced Pancreatic Ductal Adenocarcinoma: Moving Forward.
    • Franck C, Müller C, Rosania R, Croner RS, Pech M, Venerito M.
    • Cancers (Basel). 2020 Jul 18;12(7):E1955. doi: 10.3390/cancers12071955.
    • A Phase I/II Study of Veliparib (ABT-888) in combination with 5-Fluorouracil and Oxaliplatin in Patients with Metastatic Pancreatic Cancer.
    • Pishvaian MJ, Wang H, He AR, Hwang JJ, Smaglo BG, Kim SS, Weinberg BA, Weiner LM, Marshall JL, Brody JR.
    • Clin Cancer Res. 2020 Jul 15:clincanres.1301.2020. doi: 10.1158/1078-0432.CCR-20-1301. Epub ahead of print.
    • Maintenance therapies in metastatic pancreatic cancer: present and future with a focus on PARP inhibitors.
    • Hammel P, Vitellius C, Boisteau É, Wisniewski M, Colle E, Hilmi M, Dengremont C, Granier S, Turpin A, de Mestier L, Neuzillet C.
    • Ther Adv Med Oncol. 2020 Jul 9;12:1758835920937949. doi: 10.1177/1758835920937949.
    • Synthetic Lethality strategies: Beyond BRCA1/2 mutations in pancreatic cancer.
    • Hu Y, Guo M.
    • Cancer Sci. 2020 Jul 8. doi: 10.1111/cas.14565. Epub ahead of print.
    • PARP Inhibitor Lynparza Receives EU Approval for Germline BRCA-Mutated Pancreatic Cancer.
    • [No author given.]
    • Precision Oncology News. 2020 Jul 8.
    • Pancreatic cancer.
    • Mizrahi JD, Surana R, Valle JW, Shroff RT.
    • Lancet. 2020 Jun 27;395(10242):2008-2020. doi: 10.1016/S0140-6736(20)30974-0.
    • Review
    • Undifferentiated carcinoma with osteoclast-like giant cells of the pancreas harboring KRAS and BRCA mutations: case report and whole exome sequencing analysis.
    • Yang G, Yin J, Ou K, Du Q, Ren W, Jin Y, Peng L, Yang L.
    • BMC Gastroenterol. 2020 Jun 26;20(1):202. doi: 10.1186/s12876-020-01351-7.
    • Small Steps in Pancreatic Cancer – Episode 2: Relatives at Risk.
    • McAllister F, Maitra A, Burton M, McGuire M..
    • Medscape. 2020 Jun 25.
    • Phase II clinical trial of gemcitabine plus oxaliplatin in patients with metastatic pancreatic adenocarcinoma with a family history of pancreatic/breast/ovarian/prostate cancer or personal history of breast/ovarian/prostate cancer (FABRIC study).
    • Okano N, Morizane C, Nomura S, Takahashi H, Tsumura H, Satake H, Mizuno N, Tsuji K, Shioji K, Asagi A, Yasui K, Kitagawa S, Kashiwada T, Ishiguro A, Kanai M, Ueno M, Ogura T, Shimizu S, Tobimatsu K, Motoya M, Nakashima K, Ikeda M, Okusaka T, Furuse J.
    • Int J Clin Oncol. 2020 Jun 13. doi: 10.1007/s10147-020-01721-x. Epub ahead of print.
    • Identifying Patients With Pancreatic Cancer Likely to Respond.
    • Harrison P.
    • Medscape. 2020 Jun 2.

    Related:

    Original research:

    Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.

    • CHMP Issues Positive Opinion for Lynparza as Maintenance Treatment in BRCA-Mutated Pancreatic Cancer.
    • [No author given]
    • Precision Oncology News. 2020 Jun 1.
    • Germline Results From Tumor-Normal Sequencing Guides Precision Therapy in Advanced Cancer Patients.
    • Ray T.
    • Precision Oncology News. 2020 May 31.

    Related:

    Guidelines:

    Points to consider for reporting of germline variation in patients undergoing tumor testing: a statement of the American College of Medical Genetics and Genomics (ACMG).

    • Olaparib for BRCA mutant pancreas cancer: Should the POLO trial change clinical practice?
    • Nishikawa G, Booth C, Prasad V.
    • Cancer. 2020 May 27. doi: 10.1002/cncr.32979. Epub ahead of print.
    • Commentary
    • Genomic Methods Identify Homologous Recombination Deficiency in Pancreas Adenocarcinoma and Optimize Treatment Selection.
    • Park W, Chen J, Chou JF, Varghese AM, Yu KH, Wong W, Capanu M, Balachandran V, McIntyre CA, El Dika I, Khalil DN, Harding JJ, Ghalehsari N, McKinnell Z, Chalasani SB, Makarov V, Selenica P, Pei X, Lecomte N, Kelsen DP, Abou-Alfa GK, Robson ME, Zhang L, Berger MF, Schultz N, Chan TA, Powell SN, Reis-Filho JS, Iacobuzio-Donahue CA, Riaz N, O'Reilly EM.
    • Clin Cancer Res. 2020 May 22. doi: 10.1158/1078-0432.CCR-20-0418. Epub ahead of print.
    • Cisplatin Plus Gemcitabine as Standard of Care for Germline BRCA/PALB2-Mutated Pancreatic Adenocarcinoma: Are We Moving Too Fast?
    • Fazio N.
    • J Clin Oncol. 2020 May 14:JCO2000419. doi: 10.1200/JCO.20.00419. Epub ahead of print.

    Related:

    Original research:

    Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation.

    • [Molecular predictors for the course of disease and individualized therapy in pancreatic cancer].
    • Damanakis AI, Gebauer F, Bruns CJ. Molekulare Prädiktoren für den Krankheitsverlauf und die individualisierte Therapie beim Pankreaskarzinom
    • Chirurg. 2020 May 13. German. doi: 10.1007/s00104-020-01172-0. Epub ahead of print.
    • Review, [Article in German]
    • AGA Clinical Practice Update on Pancreas Cancer Screening in High Risk Individuals: Expert Review.
    • Aslanian HR, Lee JH, Canto MI.
    • Gastroenterology. 2020 May 13:S0016-5085(20)30657-0. doi: 10.1053/j.gastro.2020.03.088. Epub ahead of print.
    • Review, Practice Guideline
    • Randomized, Multicenter, Phase II Trial of Gemcitabine and Cisplatin With or Without Veliparib in Patients With Pancreas Adenocarcinoma and a Germline BRCA/PALB2 Mutation.
    • O'Reilly EM, Lee JW, Zalupski M, Capanu M, Park J, Golan T, Tahover E, Lowery MA, Chou JF, Sahai V, Brenner R, Kindler HL, Yu KH, Zervoudakis A, Vemuri S, Stadler ZK, Do RKG, Dhani N, Chen AP, Kelsen DP.
    • J Clin Oncol. 2020 May 1;38(13):1378-1388. doi: 10.1200/JCO.19.02931. Epub 2020 Jan 24.

    Related:

    Podcast, Research review: Optimizing Treatment Strategies for Germline BRCA/PALB2 Mutant Pancreatic Adenocarcinoma. (JCO Podcast. 2020 Jan 21.)

    Related:

    Letter, Comment:

    Cisplatin Plus Gemcitabine as Standard of Care for Germline BRCA/PALB2-Mutated Pancreatic Adenocarcinoma: Are We Moving Too Fast?

    • Pan-Cancer Analysis of BRCA1 and BRCA2 Genomic Alterations and Their Association With Genomic Instability as Measured by Genome-Wide Loss of Heterozygosity.
    • Sokol ES, Pavlick D, Khiabanian H, Frampton GM, Ross JS, Gregg JP, Lara PN, Oesterreich S, Agarwal N, Necchi A, Miller VA, Alexander B, Ali SM, Ganesan S, Chung JH.
    • JCO Precis Oncol. 2020;4:442. doi: 10.1200/PO.19.00345. Epub 2020 Apr 30.
    • BRCA Mutations in Pancreas Cancer: Spectrum, Current Management, Challenges and Future Prospects.
    • Wong W, Raufi AG, Safyan RA, Bates SE, Manji GA.
    • Cancer Manag Res. 2020 Apr 23;12:2731-2742. doi: 10.2147/CMAR.S211151. eCollection 2020.
    • Increased Rate of Complete Pathologic Response After Neoadjuvant FOLFIRINOX for BRCA Mutation Carriers with Borderline Resectable Pancreatic Cancer.
    • Golan T, Barenboim A, Lahat G, Nachmany I, Goykhman Y, Shacham-Shmueli E, Halpern N, Brazowski E, Geva R, Wolf I, Goldes Y, Ben-Haim M, Klausner JM, Lubezky N.
    • Ann Surg Oncol. 2020 Apr 20. doi: 10.1245/s10434-020-08469-8. [Epub ahead of print]

    Related:

    Research review, Commentary:

    ASO Author Reflections: Pancreatic Cancer Patients with Germline BRCA Mutations Benefit from Early Introduction of Platinum-Based Chemotherapy.

    • New Treatment Strategies for Metastatic Pancreatic Ductal Adenocarcinoma.
    • Singh RR, O'Reilly EM.
    • Drugs. 2020 Apr 18. doi: 10.1007/s40265-020-01304-0. [Epub ahead of print]
    • Review
    • Myriad Genetics Seeks Japan Approval for Advanced Pancreatic, Prostate Cancer Companion Diagnostic.
    • [No author given]
    • GenomeWeb. 2020 Mar 30.
    • Pancreatic Adenocarcinoma: Unconventional Approaches for an Unconventional Disease.
    • Gromisch C, Qadan M, Albuquerque Machado M, Liu K, Colson Y, Grinstaff MW.
    • Cancer Res. 2020 Mar 27:canres.2731.2019. doi: 10.1158/0008-5472.CAN-19-2731. Epub ahead of print.
    • Review
    • [Medical treatment options in BRCA-associated cancers].
    • Kahán Z.
    • Magy Onkol. 2020 Mar 17;64(1):13-24. Epub 2020 Feb 10.
    • Review, [Article in Hungarian]
    • PARP inhibitors in pancreatic cancer: molecular mechanisms and clinical applications.
    • Zhu H, Wei M, Xu J, Hua J, Liang C, Meng Q, Zhang Y, Liu J, Zhang B, Yu X, Shi S.
    • Mol Cancer. 2020 Mar 2;19(1):49. doi: 10.1186/s12943-020-01167-9.
    • Complete Response to Chemotherapy in Metastatic Pancreatic Carcinoma Associated with Double Heterozygous Germline Mutation in BRCA2 and CHEK2 Genes - a Case Report.
    • Pazderová N, Urbán V, Makovník M, Macák D, Janega P, Chovanec M, Rejleková K, Mardiak J, Mego M.
    • Klin Onkol. 2020 Spring;33(3):220-225. English. doi: 10.14735/amko2020220.
    • The role of PARP inhibitors in germline BRCA-associated pancreatic ductal adenocarcinoma.
    • Moffat GT, O'Reilly EM.
    • Clin Adv Hematol Oncol. 2020 Mar;18(3):168-179.
    • Current and emerging therapies for patients with advanced pancreatic ductal adenocarcinoma: a bright future.
    • Christenson ES, Jaffee E, Azad NS.
    • Lancet Oncol. 2020 Mar;21(3):e135-e145. doi: 10.1016/S1470-2045(19)30795-8.
    • Review
    • Acquired multiple secondary BRCA2 mutations upon PARPi resistance in a metastatic pancreatic cancer patient harboring a BRCA2 germline mutation.
    • Tao H, Liu S, Huang D, Han X, Wu X, Shao YW, Hu Y.
    • Am J Transl Res. 2020 Feb 15;12(2):612-617. eCollection 2020.
    • An Emerging Paradigm for Germline Testing in Pancreatic Ductal Adenocarcinoma and Immediate Implications for Clinical Practice: A Review.
    • Rainone M, Singh I, Salo-Mullen EE, Stadler ZK, O'Reilly EM.
    • JAMA Oncol. 2020 Feb 13. doi: 10.1001/jamaoncol.2019.5963. [Epub ahead of print]
    • Review

    Related:

    Press: Pancreatic Cancer Patients May Harbor Treatable Germline Mutations. (Medscape Oncology)

    • Routine plasma-based genotyping to comprehensively detect germline, somatic, and reversion BRCA mutations among patients with advanced solid tumors.
    • Vidula N, Rich TA, Sartor O, Yen J, Hardin A, Nance T, Lilly MB, Nezami MA, Patel SP, Carneiro BA, Fan A, Brufksy AM, Parker BA, Bridges BB, Agarwal N, Maughan BL, Raymond VM, Fairclough SR, Lanman RB, Bardia A, Cristofanilli M.
    • Clin Cancer Res. 2020 Feb 7. pii: clincanres.2933.2019. doi: 10.1158/1078-0432.CCR-19-2933. [Epub ahead of print]
    • PARP inhibitor-induced torsades de pointes in long QT syndrome: a case report.
    • Segan L, Beekman A, Parfrey S, Perrin M.
    • Eur Heart J Case Rep. 2019 Dec 31;4(1):1-5. doi: 10.1093/ehjcr/ytz230. eCollection 2020 Feb.
    • FDA Approves First PARP Inhibitor as Frontline Maintenance in Pancreatic Cancer.
    • Kahl KL.
    • Cancernetwork. 2019 Dec 30.
    • FDA Approves Myriad BRACAnalysis CDx for Lynparza in Metastatic Pancreatic Cancer.
    • [No author given]
    • Clinical OMICs. 2019 Dec 30.
    • FDA Approves AstraZeneca's Lynparza, Myriad Genetics' CDx for BRCA-Positive Pancreatic Cancer.
    • [No author given]
    • GenomeWeb. 2019 Dec 30.
    • New Option in Pancreatic Cancer: Olaparib for BRCA Mutations.
    • Chustecka Z.
    • Medscape Oncology. 2019 Dec 30.
    • LYNPARZA® (olaparib) Approved by FDA as First-Line Maintenance Treatment of Germline BRCA-Mutated Metastatic Pancreatic Cancer.
    • [No author given]
    • Merck. News Release. 2019 Dec 30.
    • Heartbreaking News, Then Tumor Find Leads to Genetic Testing.
    • Hackethal V.
    • Medscape Oncology. 2019 Dec 27.

    Related:

    Guidelines: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, NCCN Guidelines Version 1.2020. (NCCN.org. 2019 Dec 4. Version 1.2020.)

    • Germline DNA Sequencing Reveals Novel Mutations Predictive of Overall Survival in a Cohort of Pancreatic Cancer Patients.
    • Goldstein JB, Zhao L, Wang X, Ghelman Y, Overman MJ, Javle M, Shroff RT, Varadhachary GR, Wolf RA, McAllister F, Futreal PA, Fogelman DR.
    • Clin Cancer Res. 2019 Dec 23. pii: clincanres.0224.2019. doi: 10.1158/1078-0432.CCR-19-0224. [Epub ahead of print]
    • PARP Inhibitors in Pancreatic Cancer: From Phase I to Plenary Session.
    • Patel R, Fein D, Ramirez CB, Do K, Saif MW.
    • Pancreas (Fairfax). 2019;3(1):e5-e8. doi: 10.17140/POJ-3-e011. Epub 2019 Dec 20.
    • NCCN Publishes Updated Genetic Risk Assessment Recommendations.
    • Wright K.
    • Cancernetwork. 2019 Dec 18.
    • Poly(ADP-Ribose) Polymerase Inhibitors in Pancreatic Cancer: A New Treatment Paradigms and Future Implications.
    • Gupta M, Iyer R, Fountzilas C.
    • Cancers (Basel). 2019 Dec 9;11(12). pii: E1980. doi: 10.3390/cancers11121980.
    • Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation.
    • Wattenberg MM, Asch D, Yu S, O'Dwyer PJ, Domchek SM, Nathanson KL, Rosen MA, Beatty GL, Siegelman ES, Reiss KA.
    • Br J Cancer. 2019 Dec 2. doi: 10.1038/s41416-019-0582-7. [Epub ahead of print]

    Related:

    Editorial:

    Genotype–phenotype correlation in BRCA1/2 mutation-associated pancreatic cancer.

    • Genotype-phenotype correlation in BRCA1/2 mutation-associated pancreatic cancer.
    • Lowery MA.
    • Br J Cancer. 2019 Dec 2. doi: 10.1038/s41416-019-0645-9. [Epub ahead of print]
    • From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer.
    • Nevala-Plagemann C, Hidalgo M, Garrido-Laguna I.
    • Nat Rev Clin Oncol. 2019 Nov 8. doi: 10.1038/s41571-019-0281-6. [Epub ahead of print]
    • Review
    • Dramatic response of FOLFIRINOX regimen in a collision pancreatic adenocarcinoma patient with a germline BRCA2 mutation: a case report.
    • Shimmura H, Kuramochi H, Jibiki N, Katagiri S, Nishino T, Araida T.
    • Jpn J Clin Oncol. 2019 Oct 15. pii: hyz141. doi: 10.1093/jjco/hyz141. [Epub ahead of print]
    • Case report
    • A case report of a dramatic response to olaparib in a patient with metastatic pancreatic cancer harboring a germline BRCA2 mutation.
    • Wang H, Mao C, Li N, Sun L, Zheng Y, Xu N.
    • Medicine (Baltimore). 2019 Oct;98(40):e17443. doi: 10.1097/MD.0000000000017443.
    • Health-related quality of life in patients with a germline BRCA mutation and metastatic pancreatic cancer receiving maintenance olaparib.
    • Hammel P, Kindler HL, Reni M, Cutsem EV, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Joo S, Yoo HK, Patel N, Golan T.
    • Ann Oncol. 2019 Sep 28. pii: mdz406. doi: 10.1093/annonc/mdz406. [Epub ahead of print]
    • Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis.
    • Rebelatto TF, Falavigna M, Pozzari M, Spada F, Cella CA, Laffi A, Pellicori S, Fazio N.
    • Cancer Treat Rev. 2019 Sep 6;80:101895. doi: 10.1016/j.ctrv.2019.101895. [Epub ahead of print]
    • Review
    • Promising new treatments for pancreatic cancer in the era of targeted and immune therapies.
    • Elaileh A, Saharia A, Potter L, Baio F, Ghafel A, Abdelrahim M, Heyne K.
    • Am J Cancer Res. 2019 Sep 1;9(9):1871-1888. eCollection 2019.
    • Should PARP Inhibitors Have Tumor-Agnostic Approval Status?
    • Markman M.
    • Medscape Oncology. 2019 Aug 19.

    Related:

    Original research:

    Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.

    • An Analysis of Patients with DNA Repair Pathway Mutations Treated with a PARP Inhibitor.
    • Borazanci E, Korn R, Liang WS, Guarnieri C, Haag S, Snyder C, Hendrickson K, Caldwell L, Von Hoff D, Jameson G.
    • Oncologist. 2019 Aug 7. pii: theoncologist.2018-0905. doi: 10.1634/theoncologist.2018-0905. [Epub ahead of print]
    • Screening for Pancreatic Cancer.
    • Lucas AL, Kastrinos F.
    • JAMA. 2019 Aug 6;322(5):407-408. doi: 10.1001/jama.2019.9690.

    Related:

    Guidelines:

    Screening for Pancreatic Cancer: US Preventive Services Task Force Reaffirmation Recommendation Statement.

    Editorial:

    Screening for Pancreatic Cancer Gets a D, But the Student Is Improving.

    Editorial:

    Screening for Pancreatic Cancer-Is There Hope?

    • Paradigm Shifting of Systemic Chemotherapy for Unresectable Pancreatic Cancer in Japan.
    • Furuse J.
    • J Clin Med. 2019 Aug 4;8(8). pii: E1170. doi: 10.3390/jcm8081170.
    • Maintenance Olaparib New Standard in Pancreatic Cancer?
    • [No authors listed]
    • Cancer Discov. 2019 Jun 4. doi: 10.1158/2159-8290.CD-NB2019-065. [Epub ahead of print]
    • Conference news
    • Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer.
    • Golan T, Hammel P, Reni M, Van Cutsem E, Macarulla T, Hall MJ, Park JO, Hochhauser D, Arnold D, Oh DY, Reinacher-Schick A, Tortora G, Algül H, O'Reilly EM, McGuinness D, Cui KY, Schlienger K, Locker GY, Kindler HL.
    • N Engl J Med. 2019 Jun 2. doi: 10.1056/NEJMoa1903387. [Epub ahead of print]

    Related:

    Research news: Results from the POLO trial: Olaparib may delay cancer progression in metastatic pancreatic cancer patients with BRCA mutations. (FORCE. XRAYS.)

    Research news: Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer. (GenomeWeb)

    Research news: Olaparib Delays Progression in BRCA Pancreatic Cancer. (Medscape Oncology)

    Commentary, Research news: Should PARP Inhibitors Have Tumor-Agnostic Approval Status? (Medscape Oncology)

    • Pancreatic cancer in young adults: changes, challenges, and solutions.
    • Primavesi F, Stättner S, Schlick K, Kiesslich T, Mayr C, Klieser E, Urbas R, Neureiter D.
    • Onco Targets Ther. 2019 May 6;12:3387-3400. doi: 10.2147/OTT.S176700. eCollection 2019.
    • Impact of BRCA1/2 gene mutations on survival of patients with pancreatic cancer: A case-series analysis.
    • Navarro EB, López EV, Quijano Y, Caruso R, Ferri V, Durand H, Cabrera IF, Reques ED, Ielpo B, Glagolieva AY, Plaza C.
    • Ann Hepatobiliary Pancreat Surg. 2019 May;23(2):200-205. doi: 10.14701/ahbps.2019.23.2.200. Epub 2019 May 31.
    • Pancreatic acinar cell carcinoma is associated with BRCA2 germline mutations: a case report and literature review.
    • Kryklyva V, Haj Mohammad N, Morsink FHM, Ligtenberg MJL, Offerhaus GJA, Nagtegaal ID, de Leng WWJ, Brosens LAA.
    • Cancer Biol Ther. 2019 Apr 19:1-7. doi: 10.1080/15384047.2019.1595274. [Epub ahead of print]
    • Maintenance Rucaparib Controls Some Pancreatic Cancers.
    • [No authors listed]
    • Cancer Discov. 2019 Apr 2. doi: 10.1158/2159-8290.CD-NB2019-043. [Epub ahead of print]
    • PARP Inhibitors for Maintenance Therapy in Pancreatic Cancer?
    • Castellino AM.
    • Medscape. Medscape Oncology. 2019 Apr 2.

    Related:

    Conference abstract: CT234 - A Phase II, single arm study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic mutation in BRCA1, BRCA2 or PALB2 (AACR Annual Meeting 2019)

    • Familial Pancreatic Cancer and Surveillance of High-Risk Individuals.
    • Matsubayashi H, Takaori K, Morizane C, Kiyozumi Y.
    • Gut Liver. 2019 Mar 26. doi: 10.5009/gnl18449. [Epub ahead of print]
    • Genomic profiling in pancreatic ductal adenocarcinoma and a pathway towards therapy individualization: A scoping review.
    • Singh RR, Goldberg J, Varghese AM, Yu KH, Park W, O'Reilly EM.
    • Cancer Treat Rev. 2019 Mar 22;75:27-38. doi: 10.1016/j.ctrv.2019.03.003. [Epub ahead of print]
    • Review
    • Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells.
    • Roberti M, Schipani F, Bagnolini G, Milano D, Giacomini E, Falchi F, Balboni A, Manerba M, Farabegoli F, De Franco F, Robertson J, Minucci S, Pallavicini I, Di Stefano G, Girotto S, Pellicciari R, Cavalli A.
    • Eur J Med Chem. 2019 Mar 1;165:80-92. doi: 10.1016/j.ejmech.2019.01.008. Epub 2019 Jan 10.
    • Hereditary Pancreatic Cancer: A Retrospective Single-Center Study of 5143 Italian Families with History of BRCA-Related Malignancies.
    • Toss A, Venturelli M, Molinaro E, Pipitone S, Barbieri E, Marchi I, Tenedini E, Artuso L, Castellano S, Marino M, Tagliafico E, Razzaboni E, De Matteis E, Cascinu S, Cortesi L.
    • Cancers (Basel). 2019 Feb 7;11(2). pii: E193. doi: 10.3390/cancers11020193.
    • Genomic Features and Clinical Management of Patients with Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer.
    • Ohmoto A, Yachida S, Morizane C.
    • Int J Mol Sci. 2019 Jan 29;20(3). pii: E561. doi: 10.3390/ijms20030561.
    • Radiation-Induced Colitis in a Pancreatic Cancer Patient With a Germline BRCA2 Mutation: A Case Report.
    • Wolfe AR, Jain R, Pawlik TM, Walker J, Williams TM.
    • Adv Radiat Oncol. 2018 Sep 7;4(1):10-14. doi: 10.1016/j.adro.2018.08.025. eCollection 2019 Jan-Mar.
    • The Role of BRCA Testing in Hereditary Pancreatic and Prostate Cancer Families.
    • Pilarski R.
    • Am Soc Clin Oncol Educ Book. 2019 Jan;(39):79-86. doi: 10.1200/EDBK_238977.
    • Germline cancer susceptibility gene variants, somatic second hits, and survival outcomes in patients with resected pancreatic cancer.
    • Yurgelun MB, Chittenden AB, Morales-Oyarvide V, Rubinson DA, Dunne RF, Kozak MM, Qian ZR, Welch MW, Brais LK, Da Silva A, Bui JL, Yuan C, Li T, Li W, Masuda A, Gu M, Bullock AJ, Chang DT, Clancy TE, Linehan DC, Findeis-Hosey JJ, Doyle LA, Thorner AR, Ducar MD, Wollison BM, Khalaf N, Perez K, Syngal S, Aguirre AJ, Hahn WC, Meyerson ML, Fuchs CS, Ogino S, Hornick JL, Hezel AF, Koong AC, Nowak JA, Wolpin BM.
    • Genet Med. 2019 Jan;21(1):213-223. doi: 10.1038/s41436-018-0009-5. Epub 2018 Jul 2.
    • Biomarkers and pathways of chemoresistance and chemosensitivity for personalized treatment of pancreatic adenocarcinoma.
    • Zemanek T, Melichar B, Lovecek M, Soucek P, Mohelnikova-Duchonova B.
    • Pharmacogenomics. 2019 Jan;20(2):113-127. doi: 10.2217/pgs-2018-0073. Epub 2018 Dec 12.
    • Review
    • Germline and Somatic DNA Damage Repair Gene Mutations and Overall Survival in Metastatic Pancreatic Adenocarcinoma Patients Treated with FOLFIRINOX.
    • Sehdev A, Gbolahan O, Hancock BA, Stanley M, Shahda S, Wan J, Wu HH, Radovich M, O'Neil BH.
    • Clin Cancer Res. 2018 Dec 15;24(24):6204-6211. doi: 10.1158/1078-0432.CCR-18-1472. Epub 2018 Aug 21.
    • Genomic Profiling and Potentially Targetable Alterations in Pancreatic Ductal Adenocarcinoma.
    • Gleeson FC, Levy MJ.
    • Curr Treat Options Gastroenterol. 2018 Dec;16(4):441-448. doi: 10.1007/s11938-018-0195-x.
    • Review
    • Epidermal Growth Factor Receptor-Targeting Peptide Nanoparticles Simultaneously Deliver Gemcitabine and Olaparib To Treat Pancreatic Cancer with Breast Cancer 2 ( BRCA2) Mutation.
    • Du C, Qi Y, Zhang Y, Wang Y, Zhao X, Min H, Han X, Lang J, Qin H, Shi Q, Zhang Z, Tian X, Anderson GJ, Zhao Y, Nie G, Yang Y.
    • ACS Nano. 2018 Nov 27;12(11):10785-10796. doi: 10.1021/acsnano.8b01573. Epub 2018 Nov 12.
    • Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: A case report.
    • Li M, Mou Y, Hou S, Cao D, Li A.
    • Medicine (Baltimore). 2018 Nov;97(45):e13113. doi: 10.1097/MD.0000000000013113.
    • My Father’s Fight Against the Breast-Cancer Gene.
    • Munster P.
    • The Wall Street Journal. The Saturday Essay. 2018 Sep 28.

    Related:

    Blog post: Pamela Munster's story: Cancer in the family (FORCE. XRAYS.)

    • Harnessing the Immune System in Pancreatic Cancer.
    • Das S, Berlin J, Cardin D.
    • Curr Treat Options Oncol. 2018 Aug 20;19(10):48. doi: 10.1007/s11864-018-0566-5.
    • Review
    • Emerging strategies in BRCA-positive pancreatic cancer.
    • Kowalewski A, Szylberg Ł, Saganek M, Napiontek W, Antosik P, Grzanka D.
    • J Cancer Res Clin Oncol. 2018 Aug;144(8):1503-1507. doi: 10.1007/s00432-018-2666-9. Epub 2018 May 18.
    • Recapitulating the clinical scenario of BRCA-associated pancreatic cancer in pre-clinical models.
    • Golan T, Stossel C, Atias D, Buzhor E, Halperin S, Cohen K, Raitses-Gurevich M, Glick Y, Raskin S, Yehuda D, Feldman A, Schvimer M, Friedman E, Karni R, Wilson JM, Denroche RE, Lungu I, Bartlett JMS, Mbabaali F, Gallinger S, Berger R.
    • Int J Cancer. 2018 Jul 1;143(1):179-183. doi: 10.1002/ijc.31292. Epub 2018 Feb 23.
    • Brain Metastases in Pancreatic Ductal Adenocarcinoma: Assessment of Molecular Genotype-Phenotype Features-An Entity With an Increasing Incidence?
    • Jordan EJ, Lowery MA, Basturk O, Allen PJ, Yu KH, Tabar V, Beal K, Reidy DL, Yamada Y, Janjigian Y, Abou-Alfa GK, O'Reilly EM.
    • Clin Colorectal Cancer. 2018 Jun;17(2):e315-e321. doi: 10.1016/j.clcc.2018.01.009. Epub 2018 Feb 7.
    • Defects in homologous recombination repair genes are associated with good prognosis and clinical sensitivity to DNA-damaging agents in pancreatic cancer: A case report.
    • Sonnenblick A, Zick A, Maoz M, Cohen S, Kadouri L, Peretz T, Hubert A.
    • Mol Clin Oncol. 2018 May;8(5):683-685. doi: 10.3892/mco.2018.1588. Epub 2018 Mar 9.
    • Association between homologous recombination repair gene mutations and response to oxaliplatin in pancreatic cancer.
    • Kondo T, Kanai M, Kou T, Sakuma T, Mochizuki H, Kamada M, Nakatsui M, Uza N, Kodama Y, Masui T, Takaori K, Matsumoto S, Miyake H, Okuno Y, Muto M.
    • Oncotarget. 2018 Apr 13;9(28):19817-19825. doi: 10.18632/oncotarget.24865. eCollection 2018 Apr 13.
    • Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: Germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma.
    • O'Reilly EM, Lee JW, Lowery MA, Capanu M, Stadler ZK, Moore MJ, Dhani N, Kindler HL, Estrella H, Maynard H, Golan T, Segal A, Salo-Mullen EE, Yu KH, Epstein AS, Segal M, Brenner R, Do RK, Chen AP, Tang LH, Kelsen DP.
    • Cancer. 2018 Apr 1;124(7):1374-1382. doi: 10.1002/cncr.31218. Epub 2018 Jan 16.
    • BRCA1/BRCA2 Germline Mutation Carriers and Sporadic Pancreatic Ductal Adenocarcinoma.
    • Blair AB, Groot VP, Gemenetzis G, Wei J, Cameron JL, Weiss MJ, Goggins M, Wolfgang CL, Yu J, He J.
    • J Am Coll Surg. 2018 Apr;226(4):630-637.e1. doi: 10.1016/j.jamcollsurg.2017.12.021. Epub 2018 Jan 5.
    • Homologous Recombination Deficiency in Patients With Pancreatic Ductal Adenocarcinoma and Response to Chemotherapy.
    • Shahda S, Timms KM, Ibrahim AA, Reid JE, Cramer HM, Radovich M, Ibrahim S, Allen B, O’Neil BH
    • JCO Precis Oncol. doi: 10.1200/PO.17.00087. Epub 2017 Jan 19.

    Related:

    Editorial:

    Should We Lower Our Threshold for Germline Genetic Assessment in Pancreatic Adenocarcinoma?

    • Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline BRCA or PALB2 Mutations.
    • Reiss KA, Yu S, Judy R, Symecko H, Nathanson KL, Domchek SM.
    • JCO Precis Oncol. doi: 10.1200/PO.17.00152. Epub 2018 Jan 19.

    Related:

    Free full text: Retrospective Survival Analysis of Patients With Advanced Pancreatic Ductal Adenocarcinoma and Germline BRCA or PALB2 Mutations. (Medscape Oncology)

    Related:

    Editorial:

    Should We Lower Our Threshold for Germline Genetic Assessment in Pancreatic Adenocarcinoma?

    • Surfaceome profiling enables isolation of cancer-specific exosomal cargo in liquid biopsies from pancreatic cancer patients.
    • Castillo J, Bernard V, San Lucas FA, Allenson K, Capello M, Kim DU, Gascoyne P, Mulu FC, Stephens BM, Huang J, Wang H, Momin AA, Jacamo RO, Katz M, Wolff R, Javle M, Varadhachary G, Wistuba II, Hanash S, Maitra A, Alvarez H.
    • Ann Oncol. 2018 Jan 1;29(1):223-229. doi: 10.1093/annonc/mdx542.
    • Phase II trial of veliparib in patients with previously treated BRCA-mutated pancreas ductal adenocarcinoma.
    • Lowery MA, Kelsen DP, Capanu M, Smith SC, Lee JW, Stadler ZK, Moore MJ, Kindler HL, Golan T, Segal A, Maynard H, Hollywood E, Moynahan M, Salo-Mullen EE, Do RKG, Chen AP, Yu KH, Tang LH, O'Reilly EM.
    • Eur J Cancer. 2018 Jan;89:19-26. doi: 10.1016/j.ejca.2017.11.004. Epub 2017 Dec 8.
    • Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation.
    • Shroff RT, Hendifar A, McWilliams RR, Geva R, Epelbaum R, Rolfe L, Goble S, Lin KK, Biankin AV, Giordano H, Vonderheide RH, Domchek SM.
    • JCO Precis Oncol. 2018;2018. doi: 10.1200/PO.17.00316. Epub 2018 May 16.
    • Targeting Defects in the Cellular DNA Damage Response for the Treatment of Pancreatic Ductal Adenocarcinoma.
    • Schmitt A, Feldmann G, Zander T, Reinhardt HC.
    • Oncol Res Treat. 2018;41(10):619-625. doi: 10.1159/000493401. Epub 2018 Sep 28.
    • Risk factors, biomarker and imaging techniques used for pancreatic cancer screening.
    • Thomas C.
    • Chin Clin Oncol. 2017 Dec;6(6):61. doi: 10.21037/cco.2017.12.06.
    • Familial Pancreatic Cancer and the Future of Directed Screening.
    • Welinsky S, Lucas AL.
    • Gut Liver. 2017 Nov 15;11(6):761-770. doi: 10.5009/gnl16414.
    • Family history of pancreatic cancer in BRCA1/2 testing criteria.
    • Toss A, Venturelli M, Pipitone S, Marchi I, Tenedini E, Medici V, Tagliafico E, Razzaboni E, Spaggiari F, De Matteis E, Cascinu S, Cortesi L.
    • Ann Oncol. 2017 Oct;28 Suppl 6:vi46. doi: 10.1093/annonc/mdx425.005.
    • DNA Repair Dysfunction in Pancreatic Cancer: A Clinically Relevant Subtype for Drug Development.
    • Golan T, Javle M.
    • J Natl Compr Canc Netw. 2017 Aug;15(8):1063-1069. doi: 10.6004/jnccn.2017.0133.
    • Review
    • Olaparib in combination with irinotecan, cisplatin, and mitomycin c in patients with advanced pancreatic cancer.
    • Yarchoan M, Myzak MC, Johnson Iii BA, De Jesus-Acosta A, Le DT, Jaffee EM, Azad NS, Donehower RC, Zheng L, Oberstein PE, Fine RL, Laheru DA, Goggins M.
    • Oncotarget. 2017 Jul 4;8(27):44073-44081. doi: 10.18632/oncotarget.17237.
    • Hereditary pancreatic cancer: related syndromes and clinical perspective.
    • Carrera S, Sancho A, Azkona E, Azkuna J, Lopez-Vivanco G.
    • Hered Cancer Clin Pract. 2017 Jun 28;15:9. doi: 10.1186/s13053-017-0069-6. eCollection 2017.
    • Pancreatic Adenocarcinoma: Improving Prevention and Survivorship.
    • Sohal DPS, Willingham FF, Falconi M, Raphael KL, Crippa S.
    • Am Soc Clin Oncol Educ Book. [Presented Monday, June 5, 2017.] 2017;37:301-310. doi: 10.14694/EDBK_175222.
    • Association of Distinct Mutational Signatures With Correlates of Increased Immune Activity in Pancreatic Ductal Adenocarcinoma.
    • Connor AA, Denroche RE, Jang GH, Timms L, Kalimuthu SN, Selander I, McPherson T, Wilson GW, Chan-Seng-Yue MA, Borozan I, Ferretti V, Grant RC, Lungu IM, Costello E, Greenhalf W, Palmer D, Ghaneh P, Neoptolemos JP, Buchler M, Petersen G, Thayer S, Hollingsworth MA, Sherker A, Durocher D, Dhani N, Hedley D, Serra S, Pollett A, Roehrl MH, Bavi P, Bartlett JM, Cleary S, Wilson JM, Alexandrov LB, Moore M, Wouters BG, McPherson JD, Notta F, Stein LD, Gallinger S.
    • JAMA Oncol. 2017 Jun 1;3(6):774-783. doi: 10.1001/jamaoncol.2016.3916.
    • Phase I, Dose-Escalation, 2-Part Trial of Poly(ADP-Ribose) Polymerase Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.
    • de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, Henshaw JW, Herriott A, Patterson M, Curtin NJ, Byers LA, Wainberg ZA.
    • Cancer Discov. 2017 Jun;7(6):620-629. doi: 10.1158/2159-8290.CD-16-1250. Epub 2017 Feb 27.
    • Predictive and prognostic biomarkers in personalized gastrointestinal cancer treatment.
    • Verdaguer H, Saurí T, Macarulla T.
    • J Gastrointest Oncol. 2017 Jun;8(3):405-417. doi: 10.21037/jgo.2016.11.15.
    • BRCA1 missense polymorphisms are associated with poor prognosis of pancreatic cancer patients in a Chinese population.
    • Zhu Y, Zhai K, Ke J, Li J, Gong Y, Yang Y, Tian J, Zhang Y, Zou D, Peng X, Gong J, Zhong R, Huang K, Chang J, Miao X.
    • Oncotarget. 2017 May 30;8(22):36033-36039. doi: 10.18632/oncotarget.16422.
    • Pancreatic Adenocarcinoma: Improving Prevention and Survivorship.
    • Sohal DPS, Willingham FF, Falconi M, Raphael KL, Crippa S.
    • Am Soc Clin Oncol Educ Book. 2017 May;(37):301-310. doi: 10.1200/EDBK_175222.
    • Germline mutations in pancreatic cancer and potential new therapeutic options.
    • Pihlak R, Valle JW, McNamara MG.
    • Oncotarget. 2017 Apr 20;8(42):73240-73257. doi: 10.18632/oncotarget.17291. eCollection 2017 Sep 22.
    • BRCA2 secondary mutation-mediated resistance to platinum and PARP inhibitor-based therapy in pancreatic cancer.
    • Pishvaian MJ, Biankin AV, Bailey P, Chang DK, Laheru D, Wolfgang CL, Brody JR.
    • Br J Cancer. 2017 Apr 11;116(8):1021-1026. doi: 10.1038/bjc.2017.40. Epub 2017 Mar 14.
    • Overall survival and clinical characteristics of BRCA mutation carriers with stage I/II pancreatic cancer.
    • Golan T, Sella T, O'Reilly EM, Katz MH, Epelbaum R, Kelsen DP, Borgida A, Maynard H, Kindler H, Friedmen E, Javle M, Gallinger S.
    • Br J Cancer. 2017 Mar 14;116(6):697-702. doi: 10.1038/bjc.2017.19. Epub 2017 Feb 9.
    • Familial pancreatic cancer: Concept, management and issues.
    • Matsubayashi H, Takaori K, Morizane C, Maguchi H, Mizuma M, Takahashi H, Wada K, Hosoi H, Yachida S, Suzuki M, Usui R, Furukawa T, Furuse J, Sato T, Ueno M, Kiyozumi Y, Hijioka S, Mizuno N, Terashima T, Mizumoto M, Kodama Y, Torishima M, Kawaguchi T, Ashida R, Kitano M, Hanada K, Furukawa M, Kawabe K, Majima Y, Shimosegawa T.
    • World J Gastroenterol. 2017 Feb 14;23(6):935-948. doi: 10.3748/wjg.v23.i6.935.
    • Effects of Combined Treatment with Ionizing Radiation and the PARP Inhibitor Olaparib in BRCA Mutant and Wild Type Patient-Derived Pancreatic Cancer Xenografts.
    • Lohse I, Kumareswaran R, Cao P, Pitcher B, Gallinger S, Bristow RG, Hedley DW.
    • PLoS One. 2016 Dec 29;11(12):e0167272. doi: 10.1371/journal.pone.0167272. eCollection 2016.
    • Therapeutic potential of taxanes in the treatment of metastatic pancreatic cancer.
    • Lemstrova R, Melichar B, Mohelnikova-Duchonova B.
    • Cancer Chemother Pharmacol. 2016 Dec;78(6):1101-1111. Epub 2016 Jun 1.
    • Review
    • BRCA2: a grown-up cancer susceptibility gene.
    • Foulkes WD, Sugano K.
    • Endocr Relat Cancer. 2016 Oct;23(10):E1-E3.

    Related:

    Review:

    BRCA2 functions: from DNA repair to replication fork stabilization.

    Review:

    Defects in homologous recombination repair behind the human diseases: FA and HBOC.

    Review:

    Synthetic lethality: the road to novel therapies for breast cancer.

    Review:

    Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers.

    Review:

    Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers.

    • Pancreatic ductal adenocarcinoma in BRCA2 mutation carriers.
    • de Mestier L, Danset JB, Neuzillet C, Rebours V, Cros J, Soufir N, Hammel P.
    • Endocr Relat Cancer. 2016 Oct;23(10):T57-T67. Epub 2016 Aug 10.

    Related:

    Introductory article, Editorial:

    BRCA2: a grown-up cancer susceptibility gene.

    • Is it time to split strategies to treat homologous recombinant deficiency in pancreas cancer?
    • Teo MY, O'Reilly EM.
    • J Gastrointest Oncol. 2016 Oct;7(5):738-749.
    • Insights on Hereditary Pancreatic Cancer.
    • Michael J Hall
    • FORCE. Be Empowered Webinars. 2016 Sep 6.
    • Perspectives on the combination of radiotherapy and targeted therapy with DNA repair inhibitors in the treatment of pancreatic cancer.
    • Yang SH, Kuo TC, Wu H, Guo JC, Hsu C, Hsu CH, Tien YW, Yeh KH, Cheng AL, Kuo SH.
    • World J Gastroenterol. 2016 Aug 28;22(32):7275-88. doi: 10.3748/wjg.v22.i32.7275.
    • Genomic instability in pancreatic adenocarcinoma: a new step towards precision medicine and novel therapeutic approaches.
    • Sahin IH, Lowery MA, Stadler ZK, Salo-Mullen E, Iacobuzio-Donahue CA, Kelsen DP, O'Reilly EM.
    • Expert Rev Gastroenterol Hepatol. 2016 Aug;10(8):893-905. doi: 10.1586/17474124.2016.1153424. Epub 2016 Feb 26.
    • Review
    • Genetic Testing in Pancreatic Ductal Adenocarcinoma: Implications for Prevention and Treatment.
    • Peters ML, Tseng JF, Miksad RA.
    • Clin Ther. 2016 Jul;38(7):1622-35. doi: 10.1016/j.clinthera.2016.03.006. Epub 2016 Apr 1.
    • Changing the course of pancreatic cancer - Focus on recent translational advances.
    • Javle M, Golan T, Maitra A.
    • Cancer Treat Rev. 2016 Mar;44:17-25. doi: 10.1016/j.ctrv.2016.01.004. Epub 2016 Jan 25.
    • Review
    • Molecular signature of pancreatic adenocarcinoma: an insight from genotype to phenotype and challenges for targeted therapy.
    • Sahin IH, Iacobuzio-Donahue CA, O'Reilly EM.
    • Expert Opin Ther Targets. 2016 Mar;20(3):341-59. doi: 10.1517/14728222.2016.1094057. Epub 2015 Oct 6.
    • Re: "Clinical Sequencing Contributes to a BRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course".
    • Klauschen F, Bläker H, Stenzinger A, Chapman JS, Collisson EA, Taylor BS.
    • J Natl Compr Canc Netw. 2016 Mar;14(3):lxvi-lxviii.
    • Letter

    Related:

    Case report

    Clinical Sequencing Contributes to a BRCA-Associated Cancer Rediagnosis That Guides an Effective Therapeutic Course.

    Response / Letter

    The Authors Respond.

    • Biweekly gemcitabine and low-dose cisplatin in the treatment of locally advanced or metastatic pancreatic cancer patients: a single institute experience.
    • Lundberg J, Reardon J, Blazer M, Phillips G, Bekaii-Saab T.
    • Med Oncol. 2016 Jan;33(1):4. doi: 10.1007/s12032-015-0720-x. Epub 2015 Dec 22.
    • The Role of BRCA2 Mutation Status as Diagnostic, Predictive, and Prognosis Biomarker for Pancreatic Cancer.
    • Martinez-Useros J, Garcia-Foncillas J.
    • Biomed Res Int. 2016;2016:1869304. doi: 10.1155/2016/1869304. Epub 2016 Dec 18.
    • Diagnosis and Management of Hereditary Pancreatic Cancer.
    • Humphris JL, Biankin AV.
    • Recent Results Cancer Res. 2016;205:61-83. doi: 10.1007/978-3-319-29998-3_5.
    • Adenosquamous Carcinoma of the Pancreas in a Patient with BRCA2 Mutation: A Case Report.
    • Yeung V, Palmer JD, Williams N, Weinstein JC, Fortuna D, Sama A, Winter J, Bar-Ad V.
    • Case Rep Pancreat Cancer. 2015 Nov 1;1(1):22-25. doi: 10.1089/crpc.2015.29003.vye. eCollection 2015.
    • Prolonged Survival in a Patient with a Pancreatic Acinar Cell Carcinoma.
    • Ploquin A, Baldini C, Vuagnat P, Makhloufi S, Desauw C, Hebbar M.
    • Case Rep Oncol. 2015 Oct 22;8(3):447-450. doi: 10.1159/000441414.
    • Pancreatic cancer: BRCA mutation and personalized treatment.
    • Luo G, Lu Y, Jin K, Cheng H, Guo M, Liu Z, Long J, Liu C, Ni Q, Yu X.
    • Expert Rev Anticancer Ther. 2015 Oct;15(10):1223-31. doi: 10.1586/14737140.2015.1086271. Epub 2015 Sep 7.
    • Review
    • To BRCA or Not to PALB.
    • McNamara MG, Lamarca A, Hubner RA, Valle JW.
    • J Clin Oncol. 2015 Aug 10;33(23):2581-2. doi: 10.1200/JCO.2014.60.0585. Epub 2015 Jun 29.

    Related:

    Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.

    Letter

    Reply to M.G. McNamara et al and M.S. Copur et al.

    • Increased in vitro and in vivo sensitivity of BRCA2-associated pancreatic cancer to the poly(ADP-ribose) polymerase-1/2 inhibitor BMN 673.
    • Andrei AZ, Hall A, Smith AL, Bascuñana C, Malina A, Connor A, Altinel-Omeroglu G, Huang S, Pelletier J, Huntsman D, Gallinger S, Omeroglu A, Metrakos P, Zogopoulos G.
    • Cancer Lett. 2015 Aug 1;364(1):8-16. doi: 10.1016/j.canlet.2015.04.003. Epub 2015 Apr 9.
    • BRCA1 and BRCA2 mutations sensitize to chemotherapy in patient-derived pancreatic cancer xenografts.
    • Lohse I, Borgida A, Cao P, Cheung M, Pintilie M, Bianco T, Holter S, Ibrahimov E, Kumareswaran R, Bristow RG, Tsao MS, Gallinger S, Hedley DW.
    • Br J Cancer. 2015 Jul 28;113(3):425-432. doi: 10.1038/bjc.2015.220. Epub 2015 Jul 16.
    • Clinical outcomes in pancreatic adenocarcinoma associated with BRCA-2 mutation.
    • Vyas O, Leung K, Ledbetter L, Kaley K, Rodriguez T, Garcon MC, Saif MW.
    • Anticancer Drugs. 2015 Feb;26(2):224-6. doi: 10.1097/CAD.0000000000000178.
    • Olaparib monotherapy in patients with advanced cancer and a germline BRCA1/2 mutation.
    • Kaufman B, Shapira-Frommer R, Schmutzler RK, Audeh MW, Friedlander M, Balmaña J, Mitchell G, Fried G, Stemmer SM, Hubert A, Rosengarten O, Steiner M, Loman N, Bowen K, Fielding A, Domchek SM.
    • J Clin Oncol. 2015 Jan 20;33(3):244-50. doi: 10.1200/JCO.2014.56.2728. Epub 2014 Nov 3.

    Related:

    Comment / Letter

    Germline BRCA1/2 Mutations: Are They Good Enough to Determine Who Will Respond to Poly(ADP-Ribose) Polymerase Inhibitor Therapy in Advanced Cancer?

    Letter

    To BRCA or Not to PALB.

    Letter

    Reply to M.G. McNamara et al and M.S. Copur et al.

    Comment / Editorial

    The Long and Winding Road.

    Press: Olaparib Trial Offers a Look at Precision Medicine's Future. (Medscape Oncology)

    • Olaparib effective in four advanced cancers.
    • [No authors listed]
    • Cancer Discov. 2015 Jan;5(1):OF3. doi: 10.1158/2159-8290.CD-NB2014-176. Epub 2014 Dec 9.
    • Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers.
    • Golan T, Kanji ZS, Epelbaum R, Devaud N, Dagan E, Holter S, Aderka D, Paluch-Shimon S, Kaufman B, Gershoni-Baruch R, Hedley D, Moore MJ, Friedman E, Gallinger S.
    • Br J Cancer. 2014 Sep 9;111(6):1132-1138. doi: 10.1038/bjc.2014.418. Epub 2014 Jul 29.
    • PARP-Inhibitors in BRCA-Associated Pancreatic Cancer.
    • Bhalla A, Saif MW.
    • JOP. 2014 Jul 28;15(4):340-3. doi: 10.6092/1590-8577/2690.
    • PARP Inhibitors for BRCA1/2 mutation-associated and BRCA-like malignancies.
    • Lee JM, Ledermann JA, Kohn EC.
    • Ann Oncol. 2014 Jan;25(1):32-40. doi: 10.1093/annonc/mdt384. Epub 2013 Nov 12.
    • BRCA and Pancreatic Cancer.
    • Brennan GT, Relias V, Saif MW.
    • JOP. 2013 Jul 10;14(4):325-8. doi: 10.6092/1590-8577/1652.
    • Olaparib shows promise in multiple tumor types.
    • [No authors listed]
    • Cancer Discov. 2013 Jul;3(7):OF5. doi: 10.1158/2159-8290.CD-NB2013-082. Epub 2013 Jun 6.
    • Toward a better understanding of pancreatic ductal adenocarcinoma: glimmers of hope?
    • Partensky C.
    • Pancreas. 2013 Jul;42(5):729-39. doi: 10.1097/MPA.0b013e318288107a.
    • Review
    • PARP Inhibitors Hold Promise in Pancreas Cancer.
    • Eileen O'Reilly.
    • Medscape Medical News. Medscape Oncology. 2013 Annual Meeting of the American Society of Clinical Oncology. 2013 Jun 17.
    • Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity.
    • Porcelli L, Quatrale AE, Mantuano P, Leo MG, Silvestris N, Rolland JF, Carioggia E, Lioce M, Paradiso A, Azzariti A.
    • Mol Oncol. 2013 Jun;7(3):308-22. doi: 10.1016/j.molonc.2012.10.002. Epub 2012 Oct 29.
    • BRCA-associated pancreatic cancer: the evolving management.
    • Leung K, Saif MW.
    • JOP. 2013 Mar 10;14(2):149-51. doi: 10.6092/1590-8577/1462.
    • BRCA2 Dysfunction Promotes Malignant Transformation of Pancreatic Intraepithelial Neoplasia.
    • Wang Q, Liu H, Liu T, Shu S, Jiang H, Cheng S, Yuan Y, Yang W, Wang L.
    • Anticancer Agents Med Chem. 2013 Feb 1;13(2):261-9.
    • Evaluation of candidate biomarkers to predict cancer cell sensitivity or resistance to PARP-1 inhibitor treatment.
    • Oplustilova L, Wolanin K, Mistrik M, Korinkova G, Simkova D, Bouchal J, Lenobel R, Bartkova J, Lau A, O'Connor MJ, Lukas J, Bartek J.
    • Cell Cycle. 2012 Oct 15;11(20):3837-50. doi: 10.4161/cc.22026. Epub 2012 Sep 14.

    Related:

    Comment:

    Addicted to PAR? A closer look at PARP inhibitor sensitivity.

    Comment:

    Predicting PARP inhibitor sensitivity and resistance.

    • BRCA and pancreatic cancer: selection of chemotherapy.
    • Kim R, Byer J, Saif MW.
    • JOP. 2012 Mar 10;13(2):180-1.